Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Juno Therapeutics' Stock Dropped 20% in December

By George Budwell - Jan 7, 2016 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Juno Therapeutics' stock hit the skids in December after the company updated investors on the progress of its modified T-cell therapeutic platform.

JUNO Chart

JUNO data by YCharts.

What: Juno Therapeutics (JUNO), a clinical-stage cancer immunotherapy company, saw its shares lose more than 20% of their value in December, according to data provided by S&P Capital IQ. The stock's decline was apparently driven by the company's array of clinical updates provided at the American Society of Hematology meeting last month. 

So what: Although Juno reported that its chimeric antigen receptor (CAR) T cell product candidates, JCAR015 and JCAR014, showed encouraging clinical responses in patients with relapsed or refractory acute lymphoblastic leukemia, a fair number patients in some trials experienced serious side effects such as cytokine release syndrome and/or neurotoxicity.

Such adverse effects are a well-known problem associated with CAR T-cell therapies in general. That's why some of Juno's main competitors like Bellicum Pharmaceuticals (BLCM -1.27%) are working diligently on so-called "suicide switches" that can reduce the risks of these potent cancer-fighting therapies.

Now what: Juno has reportedly built in its own version of a safety switch into some of its modified T cell therapies, including JCAR014. However, Bellicum's novel Chemical Induction of Dimerization, or CID, technology, that underlies its safety switch and can safely be triggered by the small molecule called rimiducid, is starting to look like it could potentially be a best-in-class mechanism based on some preliminary clinical trial data released last year.

As a result, there's been some chatter among industry experts that Juno, or perhaps other CAR T players, may consider licensing Bellicum's CID technology at some point in the future. While I think it's probably premature to talk about licensing deals yet, given that all of these therapies are in early to midstage development, the market is obviously deeply concerned about these overarching safety problems inherent to CAR T-cell therapies as a whole. Therefore, investors may want to proceed with caution with some of these CAR T developers for the moment, especially those like Juno that have seen their market caps swell in relatively short periods of time.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.
Bellicum Pharmaceuticals, Inc. Stock Quote
Bellicum Pharmaceuticals, Inc.
$1.56 (-1.27%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.